PDCD1 and central nervous system cancer: With the advancement of immunotherapy in clinical trials, several studies demonstrate that TMB values and expression of immune checkpoints such as PD1 are not practical indicators to discriminate beneficiaries of immunotherapy for glioma (McGrail et al., 2021).